Drug intelligence / Profile preview

SDV1001

Development stage: Preclinical
Lead developer: Auricula Biosciences
Modality: Small Molecules

Overview

SDV1001 is a small molecule prodrug developed by Syndivia for the treatment of various cancers, including pancreatic, colorectal, and triple-negative breast cancer. It is also being developed as a pan-KRAS therapeutic approach by Auricula Biosciences. The drug targets the tumor microenvironment and is designed to overcome resistance mechanisms associated with conventional KRAS inhibitors.

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on SDV1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SDV1001.

Explore the full profile